A neurologist orders the wrong genetic test for a patient experiencing peripheral neuropathy and doesn't realize it even upon ...

The trials are evaluating an individualized neoantigen vaccine with Keytruda as an adjuvant therapy for non-small cell lung cancer.

The firm plans to put the proceeds toward further developing its cell therapy in CD33- or FLT3-expressing AML and for other R&D activities.

The agency is also evaluating if there's a need for further regulatory action based on reports of hematologic malignancies from clinical trials of the therapy.

The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

NEW YORK – BeiGene on Wednesday said the European Commission approved the anti-PD-1 monoclonal antibody Tevimbra (tislelizumab) with chemotherapy as a first-line treatment for esophageal squamous cell ...